Kimberly P. Newton

Kimberly P. Newton

Auto-generated profile, based on publicly available information

Kimberly P. Newton

Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
JSJeffrey B. Schwimmer
Jeffrey B. Schwimmer
MMMichael S. Middleton
Michael S. Middleton
CBCynthia Behling
Cynthia Behling
KNKimberly P. Newton
Kimberly P. Newton
HAHannah I. Awai
Hannah I. Awai
CSClaude B. Sirlin
Claude B. Sirlin
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children. In order to advance the field of NAFLD, noninvasive imaging methods for measuring liver fat are needed. Advanced magnetic resonance imaging (MRI) has shown great promise for the quantitative assessment of hepatic steatosis but has not been validated in children. Therefore, this study was designed to evaluate the correlation and diagnostic accuracy of MRI‐estimated liver proton density fat fraction (PDFF), a biomarker for hepatic steatosis, compared to histologic steatosis grade in children. The study included 174 children with a mean age of 14.0 years. Liver PDFF estimated by MRI was significantly (P < 0.01) correlated (0.725) with steatosis grade. The correlation of MRI‐estimated liver PDFF and steatosis grade was influenced by both sex and fibrosis stage. The correlation was significantly (P < 0.01) stronger in girls (0.86) than in boys (0.70). The correlation was significantly (P < 0.01) weaker in children with stage 2‐4 fibrosis (0.61) than children with no fibrosis (0.76) or stage 1 fibrosis (0.78). The diagnostic accuracy of commonly used threshold values to distinguish between no steatosis and mild steatosis ranged from 0.69 to 0.82. The overall accuracy of predicting the histologic steatosis grade from MRI‐estimated liver PDFF was 56%. No single threshold had sufficient sensitivity and specificity to be considered diagnostic for an individual child. Conclusions: Advanced magnitude‐based MRI can be used to estimate liver PDFF in children, and those PDFF values correlate well with steatosis grade by liver histology. Thus, magnitude‐based MRI has the potential for clinical utility in the evaluation of NAFLD, but at this time no single threshold value has sufficient accuracy to be considered diagnostic for an individual child. (Hepatology 2015;61:1887–1895)

11 May 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
JSJeffrey B. Schwimmer
Jeffrey B. Schwimmer
CBCynthia Behling
Cynthia Behling
JAJorge Eduardo Angeles
Jorge Eduardo Angeles
MPMelissa Paiz
Melissa Paiz
JDJanis Durelle
Janis Durelle
CSClaude B. Sirlin
Claude B. Sirlin

4 April 2016 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
JAJonathan A. Africa
Jonathan A. Africa
KNKimberly P. Newton
Kimberly P. Newton
JSJeffrey B. Schwimmer
Jeffrey B. Schwimmer

15 December 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CCCatherine C. Cohen
Catherine C. Cohen
KLKelvin W. Li
Kelvin W. Li
AAAdina Alazrkai
Adina Alazrkai
CBCarine Beysen
Carine Beysen
CCCarissa A. Carrier
Carissa A. Carrier
MVMiriam Vos
Miriam Vos
BACKGROUND. Hepatic de novo lipogenesis (DNL) is elevated in nonalcoholic fatty liver disease (NAFLD). Improvements in hepatic fat by dietary sugar reduction may be mediated by reduced DNL, but data are limited, especially in children. We examined the effects of 8 weeks of dietary sugar restriction on hepatic DNL in adolescents with NAFLD and correlations between DNL and other metabolic outcomes. METHODS. Adolescent boys with NAFLD (n = 29) participated in an 8-week, randomized controlled trial comparing a diet low in free sugars versus their usual diet. Hepatic DNL was measured as percentage contribution to plasma triglyceride palmitate using a 7-day metabolic labeling protocol with heavy water. Hepatic fat was measured by magnetic resonance imaging–proton density fat fraction. RESULTS. Hepatic DNL was significantly decreased in the treatment group (from 34.6% to 24.1%) versus the control group (33.9% to 34.6%) (adjusted week 8 mean difference: –10.6% [95% CI: –19.1%, –2.0%]), which was paralleled by greater decreases in hepatic fat (25.5% to 17.9% vs. 19.5% to 18.8%) and fasting insulin (44.3 to 34.7 vs. 35.5 to 37.0 μIU/mL). Percentage change in DNL during the intervention correlated significantly with changes in free-sugar intake (r = 0.48, P = 0.011), insulin (r = 0.40, P = 0.047), and alanine aminotransferase (ALT) (r = 0.39, P = 0.049), but not hepatic fat (r = 0.13, P = 0.532). CONCLUSION. Our results suggest that dietary sugar restriction reduces hepatic DNL and fasting insulin, in addition to reductions in hepatic fat and ALT, among adolescents with NAFLD. These results are consistent with the hypothesis that hepatic DNL is a critical metabolic abnormality linking dietary sugar and NAFLD. TRIAL REGISTRY. ClinicalTrials.gov NCT02513121. FUNDING. The Nutrition Science Initiative (made possible by gifts from the Laura and John Arnold Foundation, Ambrose Monell Foundation, and individual donors), the UCSD Altman Clinical and Translational Research Institute, the NIH, Children’s Healthcare of Atlanta and Emory University’s Children’s Clinical and Translational Discovery Core, Children’s Healthcare of Atlanta and Emory University Pediatric Biostatistical Core, the Georgia Clinical and Translational Science Alliance, and the NIH National Institute of Diabetes, Digestive, and Kidney Disease.

22 April 2025 in Hepatology
Verified
Journal Article
Closed access
JSJeffrey B. Schwimmer
Jeffrey B. Schwimmer
NTNhat Quang N. Thai
Nhat Quang N. Thai
SNSheila L. Noon
Sheila L. Noon
PUPatricia Ugalde-Nicalo
Patricia Ugalde-Nicalo
SASabina R. Anderson
Sabina R. Anderson
CBCynthia A. Behling
Cynthia A. Behling
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children, but its long-term outcomes are poorly understood. This study aimed to quantify mortality rates, identify causes of death, and evaluate the incidence of cirrhosis and extrahepatic outcomes in children with pediatric-onset MASLD. Approach & Results: The Longitudinal InVestigation Evaluating Results of Steatosis (LIVERS) study is a single-center, retrospective cohort study conducted at Rady Children’s Hospital San Diego. We included 1,096 children aged 2–18 years who were diagnosed with MASLD between 2000 and 2017 and followed for a mean of 8.5 years. Mortality was ascertained via the National Death Index, and comorbidities were assessed through follow-up research visits and medical records. Overall, 3.4% of children died, yielding a mortality rate of 398 per 100,000 person-years; nearly half of these deaths were liver-related. Male sex and lower high-density lipoprotein levels independently predicted increased mortality risk. The cumulative incidence of cirrhosis was 4.7%. High incidence rates of extrahepatic comorbidities were observed, including dyslipidemia (3,664 per 100,000 person-years), hypertension (1,901), obstructive sleep apnea (1,185), and type 2 diabetes (911). Conclusions: Pediatric MASLD is associated with significant premature mortality and a substantial burden of hepatic and extrahepatic comorbidities. These findings highlight the need for timely screening, early intervention, and long-term management strategies to improve outcomes for children with MASLD. Export

3 January 2025 in Hepatology
Verified
Journal Article
Closed access
KNKimberly P. Newton
Kimberly P. Newton
DJDulshan Jayasekera
Dulshan Jayasekera
ABAmanda Blackford
Amanda Blackford
CBCynthia Behling
Cynthia Behling
LWLaura A. Wilson
Laura A. Wilson
FCFor The Nash Crn
For The Nash Crn
Background and Aims: Longitudinal outcomes in children with metabolic dysfunction–associated steatotic liver disease (MASLD) remain unclear due to the absence of a standardized monitoring approach. This study aimed to (1) define improvement and worsening in children with MASLD, (2) estimate rates of improvement or deterioration with the standard of care (SOC) over 1 and 2 years, and (3) identify baseline and longitudinal factors associated with improvement or worsening. Approach and Results: Using data from 2 large randomized controlled trials, we derived definitions for composite improvement and worsening of MASLD based on associations between changes in ALT, GGT, and liver histology after 1 and 2 years. Improvement was defined as ≥40% decrease in ALT and ≥20% decrease in GGT and worsening as ≥20% increase in both ALT and GGT. We applied definitions to a cohort of 440 children with MASLD. After 1 year of SOC, 22% of children with MASLD showed improvement, increasing to 31% after 2 years. However, 20% showed worsening after both 1 and 2 years despite receiving SOC. Logistic regression analysis, employing stepwise model selection, identified changes in body mass index z-score and cholesterol to be most associated with improvement or deterioration. Conclusions: This study developed criteria for improvement and worsening in children with MASLD over 1 and 2 years of follow-up. With SOC, over one-quarter of children are likely to improve while one-fifth of children are likely to worsen. Targeting interventions that affect body mass index and lipid parameters may help improve MASLD over time.